Hemab Therapeutics Doses First Volunteer in Phase 1 HMB-003 Study

MT Newswires Live09-17 20:43

Hemab Therapeutics (COAG) dosed the first healthy volunteer in a phase 1 trial evaluating investigational HMB-003 for heavy menstrual bleeding, the company said Thursday.

HMB-003 showed greater activity than tranexamic acid in preclinical models, while a single subcutaneous dose in minipigs provided about one week of sustained antifibrinolytic activity, the company said.

The randomized, placebo-controlled trial is assessing HMB-003's safety, tolerability, pharmacokinetics and pharmacodynamics in healthy adults.

Hemab expects to report results by mid-2027 that will inform development plans for heavy menstrual bleeding and other bleeding conditions, it added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2668627719?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-17 20:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2668627719","market":"us","top_or_hot":-1,"title":"Hemab Therapeutics Doses First Volunteer in Phase 1 HMB-003 Study","media":"MT Newswires Live","content":"<html><body><p> Hemab <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (COAG) dosed the first healthy volunteer in a phase 1 trial evaluating investigational HMB-003 for heavy menstrual bleeding, the company said Thursday.</p><p>HMB-003 showed greater activity than tranexamic acid in preclinical models, while a single subcutaneous dose in minipigs provided about one week of sustained antifibrinolytic activity, the company said.</p><p>The randomized, placebo-controlled trial is assessing HMB-003's safety, tolerability, pharmacokinetics and pharmacodynamics in healthy adults.</p><p>Hemab expects to report results by mid-2027 that will inform development plans for heavy menstrual bleeding and other bleeding conditions, it added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hemab Therapeutics Doses First Volunteer in Phase 1 HMB-003 Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHemab Therapeutics Doses First Volunteer in Phase 1 HMB-003 Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-17 20:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Hemab <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (COAG) dosed the first healthy volunteer in a phase 1 trial evaluating investigational HMB-003 for heavy menstrual bleeding, the company said Thursday.</p><p>HMB-003 showed greater activity than tranexamic acid in preclinical models, while a single subcutaneous dose in minipigs provided about one week of sustained antifibrinolytic activity, the company said.</p><p>The randomized, placebo-controlled trial is assessing HMB-003's safety, tolerability, pharmacokinetics and pharmacodynamics in healthy adults.</p><p>Hemab expects to report results by mid-2027 that will inform development plans for heavy menstrual bleeding and other bleeding conditions, it added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2668627719","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2668627719","pubTimestamp":1789648983,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hemab Therapeutics  dosed the first healthy volunteer in a phase 1 trial evaluating investigational HMB-003 for heavy menstrual bleeding, the company said Thursday.HMB-003 showed greater activity than tranexamic acid in preclinical models, while a single subcutaneous dose in minipigs provided about one week of sustained antifibrinolytic activity, the company said.The randomized, placebo-controlled trial is assessing HMB-003's safety, tolerability, pharmacokinetics and pharmacodynamics in healthy adults.Hemab expects to report results by mid-2027 that will inform development plans for heavy menstrual bleeding and other bleeding conditions, it added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","COAG":"Hemab Therapeutics Holdings, Inc.","BK4007":"制药","LENZ":"Therapeutics"},"translate_title":"Hemab Therapeutics 在 1 期 HMB-003 研究中为首位志愿者注射药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"COAG":1},"content_text":"Hemab Therapeutics (COAG) dosed the first healthy volunteer in a phase 1 trial evaluating investigational HMB-003 for heavy menstrual bleeding, the company said Thursday.HMB-003 showed greater activity than tranexamic acid in preclinical models, while a single subcutaneous dose in minipigs provided about one week of sustained antifibrinolytic activity, the company said.The randomized, placebo-controlled trial is assessing HMB-003's safety, tolerability, pharmacokinetics and pharmacodynamics in healthy adults.Hemab expects to report results by mid-2027 that will inform development plans for heavy menstrual bleeding and other bleeding conditions, it added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2668627719","isCrawlerRequest":true}